MX9300256A - Derivados de acido acetico y proceso para su preparacion. - Google Patents

Derivados de acido acetico y proceso para su preparacion.

Info

Publication number
MX9300256A
MX9300256A MX9300256A MX9300256A MX9300256A MX 9300256 A MX9300256 A MX 9300256A MX 9300256 A MX9300256 A MX 9300256A MX 9300256 A MX9300256 A MX 9300256A MX 9300256 A MX9300256 A MX 9300256A
Authority
MX
Mexico
Prior art keywords
represent
carbon atoms
group
hydrogen atom
alkyl group
Prior art date
Application number
MX9300256A
Other languages
English (en)
Inventor
Barry Porter Colin
David Eldred Brian
David Judkins
Henry Anderson Kelly
James Russell Wheatcroft
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929201171A external-priority patent/GB9201171D0/en
Priority claimed from GB929206004A external-priority patent/GB9206004D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX9300256A publication Critical patent/MX9300256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a derivados de ácido acético y los derivados farmacéuticamente aceptables de los mismos y sales y solvatos de los mismos, donde: X1 y Y1, representan CH o N; X2 representa CH o, cuando X1 representa CH, también puede representar N; Y2 representa N o, cuando Y1 representa N, también puede representar CH; Z representa N o N+R5; R1 representa un átomo de hidrógeno o un grupo hidroxilo, R2 representa un átomo de hidrógeno o, cuando tanto X1 y X2 representan CH, también pueden representar un átomo de flúor, cloro o bromo o un grupo alquilo de 1 a 4 átomos de carbono; R3 representa un átomo de hidrógeno o, cuando tanto Y1 y Y2 representan N, también puede representar un grupo alquilo de 1 a 4 átomos de carbono o hidroximetilo; R4 representa un átomo de hidrógeno o, cuando Z representa N, R4 también puede representar un grupo alquilo de 1 a 4 átomos de carbono; R5 representa un grupo alquilo de 1 a 4 átomos de carbono o fenilalquilo de 1 a 4 átomos de carbono; R6 representa un grupo naftilo; un grupo tiofenilo; un grupo fenilo sin sustituir; un grupo fenilo sustituido, R7 y R8, que pueden ser los mismos o diferentes representan H o alquilo de 1 a 4 átomos de carbono o, conjuntamente con el átomo de nitrógeno al cual están unidos, forman un anillo de 5 a 7 miembros saturados. Los compuestos inhiben la agregación de las plaquetas de la sangre, dependiente del fibrinógeno.
MX9300256A 1992-01-21 1993-01-20 Derivados de acido acetico y proceso para su preparacion. MX9300256A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201171A GB9201171D0 (en) 1992-01-21 1992-01-21 Chemical compounds
GB929206004A GB9206004D0 (en) 1992-03-19 1992-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
MX9300256A true MX9300256A (es) 1993-07-01

Family

ID=26300182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300256A MX9300256A (es) 1992-01-21 1993-01-20 Derivados de acido acetico y proceso para su preparacion.

Country Status (7)

Country Link
EP (1) EP0623120A1 (es)
JP (1) JPH07503459A (es)
CN (1) CN1077953A (es)
AU (1) AU3351293A (es)
IL (1) IL104446A0 (es)
MX (1) MX9300256A (es)
WO (1) WO1993014077A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
US5750754A (en) * 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
DK0691959T3 (da) * 1993-03-29 1999-04-26 Zeneca Ltd Heterocykliske derivater som blodpladeaggregations-inhibitorer
NZ262942A (en) * 1993-03-29 1997-07-27 Zeneca Ltd Pyridyl substituted piperazine and various other derivatives of azaheteroaryl substituted piperazines; pharmaceutical compositions
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
CN1113875C (zh) 1994-05-04 2003-07-09 拜尔公司 取代的芳族硫代羧酰胺及其作为除草剂的用途
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
IL116893A (en) * 1995-02-10 2000-02-29 Yamanouchi Pharma Co Ltd Piperazine derivatives and pharmaceutical compositions containing them
WO1996024583A1 (fr) * 1995-02-10 1996-08-15 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de benzamidine et leur composition medicinale
AU6318896A (en) * 1995-07-06 1997-02-05 Japan Tobacco Inc. Benzamidoxime derivatives and medicinal use thereof
DE19524765A1 (de) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR20000005117A (ko) * 1996-03-30 2000-01-25 로셰 디아그노스틱스 게엠베하 신규한 옥사졸리딘 유도체, 이들의 제조 방법 및 이들을 함유하는 약제
NZ334389A (en) * 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
DE19652919A1 (de) * 1996-12-19 1998-06-25 Solvay Pharm Gmbh Piperazinophenyl- und Piperazinophenyloxy-carbonsäure-Derivate sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AR013693A1 (es) * 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
RU2203887C2 (ru) 1998-02-27 2003-05-10 Санкио Компани, Лимитед Циклические аминопроизводные, фармацевтическая композиция и способ профилактики заболевания
CA2521621C (en) * 2003-04-15 2011-11-01 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AR051202A1 (es) 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515478A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CA2598459A1 (en) 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
JP2008530220A (ja) * 2005-02-16 2008-08-07 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、ピラジニルで置換されたピペラジン−ピペリジン
AU2006214378A1 (en) * 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
EP1858895B1 (en) * 2005-02-16 2012-06-20 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
US9738604B2 (en) 2010-09-03 2017-08-22 Duke University Ethynylbenzene derivatives
US9908851B2 (en) * 2013-08-16 2018-03-06 Duke University 2-piperidinyl substituted N,3-dihydroxybutanamides
JP6458270B2 (ja) 2013-08-16 2019-01-30 デューク ユニバーシティ 置換されたヒドロキサム酸化合物
WO2015024021A2 (en) 2013-08-16 2015-02-19 Duke University Antibacterial compounds
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11040955B2 (en) 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
CN113075343B (zh) * 2020-01-04 2024-02-23 东莞市东阳光仿制药研发有限公司 一种羟胺及其盐的检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500825B1 (fr) * 1981-02-27 1985-08-23 Torii & Co Ltd Nouveau carboxylate de 4-amidino-phenyle substitue, son procede de preparation et agent anti-complement en comprenant
US4433152A (en) * 1981-05-25 1984-02-21 Nippon Chemiphar Co., Ltd. Amidinopiperidine derivatives
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
GB9122016D0 (en) * 1991-10-16 1991-11-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IL104446A0 (en) 1993-05-13
CN1077953A (zh) 1993-11-03
EP0623120A1 (en) 1994-11-09
JPH07503459A (ja) 1995-04-13
WO1993014077A1 (en) 1993-07-22
AU3351293A (en) 1993-08-03

Similar Documents

Publication Publication Date Title
MX9300256A (es) Derivados de acido acetico y proceso para su preparacion.
ES410732A1 (es) Procedimiento para la preparacion de derivados olefinicos de piperidino-4-sustituidos.
ES445659A1 (es) Procedimiento para la obtencion de derivados olefinicos de amino acidos.
ES2055056T3 (es) Derivados de pirimidopirimidina.
PT96890A (pt) Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem
PT90805A (pt) Processo para a preparacao de 1-indolilalquil-4-(piridinil substituido)-piperazinas e de composicoes farmaceuticas que as contem
SE7501197L (es)
ATE103592T1 (de) Carbamoylpyrrolidonderivate, ihre verwendung und herstellung.
SE7908995L (sv) Heterocykliska foreningar
IE40752B1 (en) -aryl-4-substituted piperidinoalkanol derivatives
ES2036213T3 (es) Procedimiento para preparar derivados tetrahidroisoquinolin-1-ilicos de acidos carboxilicos.
GB1087243A (en) Improvements in or relating to naphthalene derivatives and the manufacture thereof
BG60338B2 (en) Thienothiazines
ES8601956A1 (es) Un metodo para preparar derivados de 3-metilflavona
PT97766A (pt) Processo depreparacao de derivados de isocromano e de composicoes farmaceuticas que os contem
ES461268A1 (es) Procedimiento de preparacion de nuevos derivados de amino- benzociclohepteno.
NO871339D0 (no) Fremgangsmaate for fremstilling av nye pyridinkarboksylsyrederivater.
NO885224D0 (no) FremgangsmŸte for fremstilling av 1,4-disubstituerte-piperidinylderivater.
AR031856A1 (es) 2-aminoalquil-tieno[2,3-d]pirimidinas
ES543790A0 (es) Procedimiento de preparacion de nuevos derivados a-etilami- noetoxibencilalcoholicos con un grupo fenil sustituido en situacion a y de sus sales de adicion acidas y amonicas cua-ternarias
SE7713968L (sv) Basiskt alkylerade ditiosalicylsyraamider, sett for framstellning derav samt anvendning derav som lekemedel
MY107827A (en) Isoquinolline compounds, compositions and use
SE8100122L (sv) Nya 2-aminometyl-6-halo-fenoler, framstellning derav och farmaceutiska kompositioner innehallande dessa
SE7713864L (sv) Nortropinkarbazatderivat och forfarande for framstellning av dem
KR860004007A (ko) 폴리사이클릭 화합물의 제조방법과 그 약학적제제